Such a serosurveillance platform could employ a similar sample collection framework to this study, or perhaps involve elution of serum from used RDTs or serological point-of-contact tests (i.e., SG6 and CSP), which would require limited additional capacity and training for expansion into current community-based malaria programs. The gene discussed is DNAJC5; the disease is malaria.